Newsletter Signup
Stay up to date on all the latest news from Boston.com
More than a year after vaccines started being available for most people, the youngest among us are still not eligible. That might soon change, and for Dr. Jeremy Faust it can’t come soon enough.
Yesterday Moderna asked the Food and Drug Administration to authorize its COVID vaccine for children under 6 years old. Pending the actual data, Faust, a Boston physician, public health researcher, and parent, said on Twitter they will vaccinate their 4-year-old daughter “ASAP” and it “will have a massive impact” on how his family lives their lives.
The vaccine measured to be 51% effective against symptomatic COVID for children ages 6 months to two years and 37% effective for ages 2 to 6.
Though these numbers may not inspire huge confidence at first glance, Faust said that the reality may be “MUCH better than that.”
Faust pointed to the way the vaccines were designed and said it’s “not really about infection.”
“What these vaccines have been shown to really do, over and over, is protect against severe disease and hospitalization, longterm consequences,” Faust wrote. “A pediatric trial can’t be large enough to detect that. But the ‘immune bridge’ strategy used both by Moderna and Pfizer has worked.”
The “immune bridge” strategy Faust is referring to involves looking at immune markers to infer vaccine efficacy — so rather than focusing solely on positive tests, it looks at if an immune response is generated by the vaccine.
“So to me, it’s huge news that they reached the antibody levels needed to imply solid protection against long-term consequences,” Faust wrote. “That’s what I care about as a parent. I’m pretty sure my kid WILL get Covid at some point, vaccine or not. But with a vaccine beforehand, she’s far less likely to suffer for very long at all.”
Faust said he will “be quite comfortable” getting his daughter vaccinated with the Moderna vaccine. If Pfizer releases data that is “TONS better” than Moderna’s before Modera’s is authorized, he said he might consider waiting a few more weeks.
“But at this point, this virus is so contagious, that the sooner you have your kid vaccinated, the better,” Faust wrote. “Getting protected sooner is what matters. It’s unlikely that there will be such differences between 3-dose Pfizer and 2-dose Moderna, though we’ll need to see.”
Read Faust’s full thread here:
The data reflect a lot of cases during Omicron.
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 28, 2022
We know these vaccines provide very good short-term protection against infection, but that's a honeymoon phase.
That's important. But the way these vaccines were designed, and how they work best, is not really about infection…
What that means is, after authorization, we've seen a bunch of studies (albeit observational, not randomized trials, like the original datasets) showing outstanding protection against severe consequences.
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 28, 2022
So to me, it's huge news that they reached the antibody levels needed…
So, in general, I prefer clinical outcomes when we look at data, as opposed proxy data; that is…"how did the kids fare?" not "what were their antibody levels?"
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 28, 2022
But in the case of the pediatric Covid vaccine data, the proxy data ("immune bridging") has worked VERY well.
If Pfizer drops new data *before Moderna is authorized and being administered, and that data is TONS better than Moderna's, than maybe we'd wait a few more weeks.
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 28, 2022
But at this point, this virus is so contagious, that the sooner you have your kid vaccinated, the better…
Long story short: pending the actual data, we'll vaccinate our 4 year old ASAP, and that will have a massive impact on how we live our lives.
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 28, 2022
Looking forward to seeing more soon.
Stay up to date on all the latest news from Boston.com
Stay up to date with everything Boston. Receive the latest news and breaking updates, straight from our newsroom to your inbox.
Conversation
This discussion has ended. Please join elsewhere on Boston.com